At present, many inhibitors specifically targeting EZH2 have been developed for the treatment of several cancers, such as relapsed or refractory follicular lymphoma,12 B‐cell lymphoma,13, 14, 15, 16, 17 advanced epithelioid sarcoma,18 advanced solid tumors,17, 19 advanced hematologic tumors,19 etc. Well‐studied inhibitors, including tazemetostat (EPZ6438),12, 13, 15, 16, 17, 18 CPI‐1205,14 CPI‐0209, GSK2816126,19 DS3210b, and PF‐06821497 are currently being tested in clinical trials.20 This evidence concerns the gene EZH2 and cancer.